Project Grant R37CA307515
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $677,379 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a cluster randomized clinical trial examining timely specialist palliative care referral and telehealth-based monitoring for patients with advanced cancer. The study, titled "Oncologic Timely Palliative Care and Remote Monitoring with Electronic Assessments and Telehealth (ON-TARGET)," will test two...
- Federal Grant Award Summary Kaiser Foundation Hospitals (Kaiser Permanente), through its Kaiser Foundation Research Institute, received a $658,743 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded on August 25, 2025, with a completion date of July 31, 2030. The grant supports development and validation of prediction models for functional trajectories, cognitive outcomes, and quality of life among adults aged 65 and older...
- The National Cancer Institute awarded Emory University $572,378 through a Cancer Biology Research Project Grant (CFDA 93.396, R01CA299279) on May 1, 2026. The recipient will investigate metabolic regulation of dormancy in disseminated non-small cell lung cancer (NSCLC) subpopulations, specifically examining how collective invasive cell packs transition from micrometastatic to macrometastatic lesions. The research applies an image-guided genomics approach to study differential genetic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of Colorado a $656,046 Project Grant on August 1, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of EASE (Exposure-based Anxiety and Symptom Elimination), a novel behavioral intervention designed to reduce fear of cancer progression (FOP) and cancer-related trauma symptoms in adults with advanced cancer. The five-year...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded Emory University $2.194 million under the Cancer Centers Support Grants program (CFDA 93.397) on August 18, 2026, to support the Emory Lung Cancer SPORE (Specialized Program of Research Excellence). The award funds a revised research program focused on three specific aims: examining novel inhibitory molecules expressed by stem-like CD8 T cells and conducting a clinical trial to evaluate a novel immunotherapy combination approach for advanced non-small cell...